Curcumin lowers erlotinib resistance in non-small cell lung carcinoma cells with mutated EGF receptor

Oncology Research

Volumn 21, Issue 3, 2013, Pages 137-144

  Li, Shanqun ^a   Liu, Zilong ^a   Zhu, Fen ^a   Fan, Xiaohong ^b   Wu, Xiaodan ^a   Zhao, Heng ^b   Jiang, Liyan ^b  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Cancer therapy; Curcumin; Drug resistance; Erlotinib; NF B; Non small cell lung cancer (NSCLC); Survivin

Indexed keywords

CASPASE 3; CASPASE 9; CURCUMIN; CYTOCHROME C; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SURVIVIN; ANTINEOPLASTIC AGENT; BIRC5 PROTEIN, HUMAN; EGFR PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; QUINAZOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CARCINOMA CELL; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; ANIMAL; BIOSYNTHESIS; DOWN REGULATION; DRUG EFFECT; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SCREENING; ENZYMOLOGY; GENETICS; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MUTATION; NUDE MOUSE; RANDOMIZATION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CURCUMIN; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LUNG NEOPLASMS; MICE; MICE, NUDE; MUTATION; QUINAZOLINES; RANDOM ALLOCATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84905058744     PISSN: 09650407     EISSN: 15553906     Source Type: Journal    
DOI: 10.3727/096504013X13832473330032     Document Type: Article

References (41)

1. Jemal, A.; Bray, F.; Center, M. M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics. CA. Cancer J. Clin. 61:69-90; 2011.
2. Chen, W. Q.; Zhang, S. W.; Zou, X. N.; Zhao, P. Cancer incidence and mortality in China, 2006. Chin. J. Cancer Res. 23:3-9; 2011.
3. Hirsch, F. R.; Jänne, P. A.; Eberhardt, W. E.; Cappuzzo, F.; Thatcher, N.; Pirker, R.; Choy, H.; Kim, E. S.; Paz-Ares, L.; Gandara, D. R. Epidermal growth factor receptor inhibition in lung cancer: Status 2012. J. Thorac. Oncol. 8:373-384; 2013.
4. Su, K. Y.; Chen, H. Y.; Li, K. C.; Kuo, M. L.; Yang, J. C.; Chan, W. K.; Ho, B. C.; Chang, G. C.; Shih, J. Y.; Yu, S. L.; Yang, P. C. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with nonsmall- cell lung cancer. J. Clin. Oncol. 30:433-440; 2012.
5. Filosto, S.; Becker, C. R.; Goldkorn, T. Cigarette smoke induces aberrant EGF receptor activation that mediates lung cancer development and resistance to tyrosine kinase inhibitors. Mol. Cancer Ther. 11:795-804; 2012.
6. Chou, Y. T.; Lin, H. H.; Lien, Y. C.; Wang, Y. H.; Hong, C. F.; Kao, Y. R.; Lin, S. C.; Chang, Y. C.; Lin, S. Y.; Chen, S. J.; Chen, H. C.; Yeh, S. D.; Wu, C. W. EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF. Cancer Res. 70:8822-8831; 2010.
7. Laskin, J. J.; Sandler, A. B. Epidermal growth factor receptor: A promising target in solid tumours. Cancer Treat. Rev. 30:1-17; 2004.
8. Glover, K. Y.; Perez-Soler, R.; Papadimitradopoulou, V. A. A review of small-molecule epidermal growth factor receptor- specific tyrosine kinase inhibitors in development for non-small cell lung cancer. Semin. Oncol. 31:83-92; 2004.
9. Haber, D. A.; Bell, D. W.; Sordella, R.; Kwak, E. L.; Godin-Heymann, N.; Sharma, S. V.; Lynch, T. J.; Settleman, J. Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors. Cold. Spring. Harb. Symp. Quant. Biol. 70:419-426; 2005.
10. Pao, W.; Miller, V.; Zakowski, M.; Doherty, J.; Politi, K.; Sarkaria, I.; Singh, B.; Heelan, R.; Rusch, V.; Fulton, L.; Mardis, E.; Kupfer, D.; Wilson, R.; Kris, M.; Varmus, H. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA 101:13306-13311; 2004.
11. Lynch, T. J.; Bell, D. W.; Sordella, R.; Gurubhagavatula, S.; Okimoto, R. A.; Brannigan, B. W.; Harris, P. L.; Haserlat, S. M.; Supko, J. G.; Haluska, F. G.; Louis, D. N.; Christiani, D. C.; Settleman, J.; Haber, D. A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350:2129-2139; 2004.
12. Pao, W.; Miller, V. A.; Politi, K. A.; Riely, G. J.; Somwar, R.; Zakowski, M. F.; Kris, M. G.; Varmus, H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2:e73; 2005.
13. Gazdar, A. F. Activating and resistance mutations of EGFR in non-small-cell lung cancer: Role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 28(Suppl. 1): S24-S31; 2009.
14. Bean, J.; Brennan, C.; Shih, J. Y.; Riely, G.; Viale, A.; Wang, L.; Chitale, D.; Motoi, N.; Szoke, J.; Broderick, S.; Balak, M.; Chang, W. C.; Yu, C. J.; Gazdar, A.; Pass, H.; Rusch, V.; Gerald, W.; Huang, S. F.; Yang, P. C.; Miller, V.; Ladanyi, M.; Yang, C. H.; Pao, W. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc. Natl. Acad. Sci. USA 104:20932-20937; 2007.
15. Normanno, N.; De Luca, A.; Bianco, C.; Strizzi, L.; Mancino, M.; Maiello, M. R.; Carotenuto, A.; De Feo, G.; Caponigro, F.; Salomon, D. S. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366:2-16; 2006.
16. Sharma, S. V.; Bell, D. W.; Settleman, J.; Haber, D. A. Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer 7:169-181; 2007.
17. Zhao, P.; Meng, Q.; Liu, L. Z.; You, Y. P.; Liu, N.; Jiang, B. H. Regulation of survivin by PI3K/Akt/p70S6K1 pathway. Biochem. Biophys. Res. Commun. 395:219-224; 2010.
18. Ambrosini, G.; Adida, C.; Altieri, D. C. A novel antiapoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med. 3:917-921; 1997.
19. Ryan, B. M.; O'Donovan, N.; Duffy, M. J. Survivin: A new target for anti-cancer therapy. Cancer Treat. Rev. 35:553- 562; 2009.
20. Weng, Y.; Fei, B.; Chi, A. L.; Cai, M. Inhibition of gastric cancer cell growth in vivo by overexpression of adenoassociated virus-mediated survivin mutant C84A. Oncol. Res. 20:411-417; 2013.
21. Okamoto, K.; Okamoto, I.; Hatashita, E.; Kuwata, K.; Yamaguchi, H.; Kita, A.; Yamanaka, K.; Ono, M.; Nakagawa, K. Overcoming erlotinib resistance in EGFR mutation-positive non-small cell lung cancer cells by targeting survivin. Mol. Cancer Ther. 11:204-213; 2012.
22. Okamoto, K.; Okamoto, I.; Okamoto, W.; Tanaka, K.; Takezawa, K.; Kuwata, K.; Yamaguchi, H.; Nishio, K.; Nakagawa, K. Role of survivin in EGFR inhibitor-induced apoptosis in non-small cell lung cancers positive for EGFR mutations. Cancer Res. 70:10402-10410; 2010.
23. Jagetia, G. C.; Aggarwal, B. B. "Spicing up" of the immune system by curcumin. J. Clin. Immunol. 27:19-35; 2007.
24. Villegas, I.; Sanchez-Fidalgo, S.; Alarcon de la Lastra, C. New mechanisms and therapeutic potential of curcumin for colorectal cancer. Mol. Nutr. Food Res. 52:1040-1061; 2008.
25. Lin, J. K. Molecular targets of curcumin. Adv. Exp. Med. Biol. 595:227-243; 2007.
26. Korutla, L.; Cheung, J. Y.; Mendelsohn, J.; Kumar, R. Inhibition of ligand-induced activation of epidermal growth factor receptor tyrosine phosphorylation by curcumin. Carcinogenesis 16:1741-1745; 1995.
27. Chen, A.; Xu, J.; Johnson, A. C. Curcumin inhibits human colon cancer cell growth by suppressing gene expression of epidermal growth factor receptor through reducing the activity of the transcription factor Egr-1. Oncogene 25:278-287; 2006.
28. Shakibaei, M.; Mobasheri, A.; Lueders, C.; Busch, F.; Shayan, P.; Goel, A. Curcumin enhances the effect of chemotherapy against colorectal cancer cells by inhibition of NF-kappaB and Src protein kinase signaling pathways. PLoS One 8:e57218; 2013.
29. Gupta, S. C.; Patchva, S.; Aggarwal, B. B. Therapeutic roles of curcumin: Lessons learned from clinical trials. AAPS J. 15:195-218; 2013.
30. de La Motte Rouge, T.; Galluzzi, L.; Olaussen, K. A.; Zermati, Y.; Tasdemir, E.; Robert, T.; Ripoche, H.; Lazar, V.; Dessen, P.; Harper, F.; Pierron, G.; Pinna, G.; Araujo, N.; Harel-Belan, A.; Armand, J. P.; Wong, T. W.; Soria, J. C.; Kroemer, G. A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib. Cancer Res. 67:6253-6262; 2007.
31. Sakuma, Y.; Yamazaki, Y.; Nakamura, Y.; Yoshihara, M.; Matsukuma, S.; Koizume, S.; Miyagi, Y. NF-κB signaling is activated and confers resistance to apoptosis in threedimensionally cultured EGFR-mutant lung adenocarcinoma cells. Biochem. Biophys. Res. Commun. 423:667-671; 2012.
32. Tanaka, K.; Babic, I.; Nathanson, D.; Akhavan, D.; Guo, D.; Gini, B.; Dang, J.; Zhu, S.; Yang, H.; De Jesus, J.; Amzajerdi, A. N.; Zhang, Y.; Dibble, C. C.; Dan, H.; Rinkenbaugh, A.; Yong, W. H.; Vinters, H. V.; Gera, J. F.; Cavenee, W. K.; Cloughesy, T. F.; Manning, B. D.; Baldwin, A. S.; Mischel, P. S. Oncogenic EGFR signaling activates an mTORC2-NF-kappaB pathway that promotes chemotherapy resistance. Cancer Discov. 1:524-538; 2011.
33. Bivona, T. G.; Hieronymus, H.; Parker, J.; Chang, K.; Taron, M.; Rosell, R.; Moonsamy, P.; Dahlman, K.; Miller, V. A.; Costa, C. FAS and NF-kappaB signalling modulate dependence of lung cancers on mutant EGFR. Nature 471:523-526; 2011.
34. Shishodia, S.; Amin, H. M.; Lai, R.; Aggarwal, B. B. Curcumin (diferuloylmethane) inhibits constitutive NF-κB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochem. Pharmacol. 70:700-713; 2005.
35. Rosell, R.; Carcereny, E.; Gervais, R.; Vergnenegre, A.; Massuti, B.; Felip, E.; Palmero, R.; Garcia-Gomez, R.; Pallares, C.; Sanchez, J. M.; Porta, R.; Cobo, M.; Garrido, P.; Longo, F.; Moran, T.; Insa, A.; De Marinis, F.; Corre, R.; Bover, I.; Illiano, A.; Dansin, E.; de Castro, J.; Milella, M.; Reguart, N.; Altavilla, G.; Jimenez, U.; Provencio, M.; Moreno, M. A.; Terrasa, J.; Munoz-Langa, J.; Valdivia, J.; Isla, D.; Domine, M.; Molinier, O.; Mazieres, J.; Baize, N.; Garcia-Campelo, R.; Robinet, G.; Rodriguez-Abreu, D.; Lopez-Vivanco, G.; Gebbia, V.; Ferrera-Delgado, L.; Bombaron, P.; Bernabe, R.; Bearz, A.; Artal, A.; Cortesi, E.; Rolfo, C.; Sanchez-Ronco, M.; Drozdowskyj, A.; Queralt, C.; de Aguirre, I.; Ramirez, J. L.; Sanchez, J. J.; Molina, M. A.; Taron, M.; Paz-Ares, L.; Spanish Lung Cancer Group in collaboration with Groupe Francais de, P.-C.; Associazione Italiana Oncologia, T. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13:239-246; 2012.
36. Zhou, C.; Wu, Y. L.; Chen, G.; Feng, J.; Liu, X. Q.; Wang, C.; Zhang, S.; Wang, J.; Zhou, S.; Ren, S.; Lu, S.; Zhang, L.; Hu, C.; Hu, C.; Luo, Y.; Chen, L.; Ye, M.; Huang, J.; Zhi, X.; Zhang, Y.; Xiu, Q.; Ma, J.; Zhang, L.; You, C. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive nonsmall- cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 12:735-742; 2011.
37. Tu, S. P.; Jin, H.; Shi, J. D.; Zhu, L. M.; Suo, Y.; Lu, G.; Liu, A.; Wang, T. C.; Yang, C. S. Curcumin induces the differentiation of myeloid-derived suppressor cells and inhibits their interaction with cancer cells and related tumor growth. Cancer Prev. Res. (Phila). 5:205-215; 2012.
38. Xue, X.; Yu, J.-L.; Sun, D.-Q.; Zou, W.; Kong, F.; Wu, J.; Liu, H.-p.; Qu, X.-J.; Wang, R.-M. Curcumin as a multidrug resistance modulator-A quick review. Biomed. Prev. Nutr. 3(2):173-176; 2013.
39. Zaffaroni, N.; Daidone, M. G. Survivin expression and resistance to anticancer treatments: Perspectives for new therapeutic interventions. Drug Resist. Updat. 5:65-72; 2002.
40. Wang, Q.; Greene, M. I. EGFR enhances Survivin expression through the phosphoinositide 3 (PI-3) kinase signaling pathway. Exp. Mol. Pathol. 79:100-107; 2005.
41. Glienke, W.; Maute, L.; Wicht, J.; Bergmann, L. Curcumin inhibits constitutive STAT3 phosphorylation in human pancreatic cancer cell lines and downregulation of survivin/ BIRC5 gene expression. Cancer Invest. 28:166-171; 2010.